tiprankstipranks
pc:atavi

Atavistik Bio

Atavistik Bio is a clinical-stage biotechnology company focused on discovering and developing precision allosteric small molecule therapeutics. The company leverages its proprietary AMPS™ platform to advance oral allosteric inhibitors targeting AKT1 for Hereditary Hemorrhagic Telangiectasia (HHT) and JAK2 V617F mutant-selective inhibitors for myeloproliferative neoplasms (MPNs).

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$120M
Total Amount Raised$120M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$120M
Latest Funding Amount$120M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation
Post-Money Valuation

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Dec 18, 2025
Series B
$120.00M

Investors

Investor Name
Funding Round

Related News and Analysis